SUNDAY, MARCH 19
Arrival and Registration

MONDAY, MARCH 20
Welcome and Keynote Address (X4)
Samuel Klein, Washington University School of Medicine, USA
Extrahepatic Lipid Processing and NAFLD/NASH

Welcome and Keynote Address (X3)
Dean Sheppard, University of California, San Francisco, USA
Fibrosis Across Organs: From Mechanisms to Therapies

Metabolic Syndrome and Diabetes as Drivers of NAFLD/NASH (X4)
Filip K. Knop, Gentofte Hospital, University of Copenhagen, Denmark
Hepatic Glucagon Action in NAFLD
Leigh A. Goedeke, Icahn School of Medicine at Mount Sinai, USA
De novo Lipogenesis and Hepatic Lipid Flux in NAFLD
Matthew Watt, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Cellular Lipid Storage and Lipotoxicity

Fibrosis Initiation Concepts: Viral Infection, Trauma, Telomere Dysfunction (X3)
Gisli Jenkins, Imperial College London, UK
Pulmonary Fibrosis in Patients with Severe COVID-19 Disease
Christine Kim Garcia, Columbia University Medical Center, USA
Telomere Dysfunction in Pulmonary Fibrosis after COVID-19 Infection
Rafael Kramann, RWTH Aachen University, Germany
Drivers of Cardiac and Kidney Fibrosis

Short Talks Chosen from Abstracts

Workshop 1: New Horizons: Emerging Preclinical Models to Study Tissue Injury, Fibrosis and Regeneration (Joint)
Short Talks Chosen from Abstracts

Fibrosis Initiation Concepts in Liver (Joint)
Quentin M. Anstee, Newcastle University, UK
Drivers of NAFLD to NASH and Fibrosis
Tatiana Kisseleva, University of California, San Diego, USA
Inflammation, Hepatic Stellate Cells, Liver Fibrosis
Thomas Fabre, Pfizer, USA
Macrophage and Fibroblast Cross-Talk in the Progression and Resolution of Fibrosis

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 21
Hepatic Lipid Management and Steatosis (X4)
Elizabeth J. Parks, University of Missouri, USA
De novo Lipogenesis and Hepatic Lipid Flux in NAFLD
Brent A. Neuschwander-Tetri, St. Louis University, USA
Lipotoxicity and NAFLD/NASH
James A. Olzmann, University of California, Berkeley, USA
Mechanisms of Cellular Lipid Storage and Lipotoxicity

Fibrosis Initiation Concepts: Aging, Oncogenic Injury, Autoimmunity (X3)
Pura Muñoz Cánoves, University Pompeu Fabra, Spain
Muscle Fibrosis and Regenerative Decline with Aging
Jörg H.W. Distler, University of Erlangen-Nuremberg, Germany
Drivers of Fibrosis in Systemic Autoimmune Rheumatic Diseases
Ellen Puré, University of Pennsylvania, USA
CAFs and their Influence on Tumor Progression and Immunity
Kang Liu, Boehringer Ingelheim Pharmaceuticals, Inc., USA
Targeting the Tumor Stroma to Cure Cancers

Short Talks Chosen from Abstracts

Workshop 2: Fibrosis Research Funding and Partnering Academia/Pharma (X3)
Short Talks Chosen from Abstracts

Pathways and Progression of NAFLD/NASH (X4)
Olivier Govaere, Newcastle University, UK
Hepatic Pathways Regulating NAFLD/NASH: Insights from Transcriptomic Approaches
Neil C. Henderson, University of Edinburgh, Queen's Medical Research Institute, UK
Insights into NASH and Liver Fibrosis from Single Cell Analyses
Jacquelyn Maher, University of California, San Francisco, USA
Advances in Understanding and Leveraging Regulatory Pathways in NAFLD/NASH

Short Talks Chosen from Abstracts

Fibrosis Drivers: Cellular Crosstalks (X3)
Valerie Horsley, Yale University, USA
Macrophage – Fibroblast Crosstalk in Tissue Repair, Regeneration and Fibrosis
Shahin Rafii, Weill Cornell Medical College, USA
Liver Sinusoidal Endothelium Dysfunction in Hepatic Fibrosis and Regeneration

* Session Chair † Invited but not yet accepted     Program current as of November 17, 2022 Meal formats are based on meeting venue.
For the most up-to-date details, visit https://www.keystonesymposia.org.
Boris Hinz, University of Toronto, Canada
Fibroblast-Macrophage Mechanobiology in Tissue Repair and Fibrosis
Short Talks Chosen from Abstracts

Edward E. Morrisey, University of Pennsylvania, USA
Lung Regeneration: Underlying Molecular Mechanisms and Emerging Concepts

Clemens A. Schmitt, Max Delbrück Center for Molecular Medicine, Germany
Virus-induced Senescence is a Driver and Therapeutic Target in COVID-19

Fibrosis Amplification Loops: Mechanobiology, Epigenetics, Senescence (X3)

Ana L. Mora, Ohio State University, USA
Cellular Senescence in Lung Fibrosis

Nan Tang, National Institute of Biological Sciences, China
Mechanobiology of Stem Cells in Tissue Regression and Fibrosis

Jelena Mann, Newcastle University, UK
Epigenetic Mechanisms in Liver Fibrosis and Cancer

Scott M. Turner, Plant Therapeutics, USA
Application of Molecular Imaging and Target Engagement Studies in the Development of PLN-74809

Fibroblastic Cells: Heterogeneity, Functions, Fate (X3)

Fabio M.V. Rossi, University of British Columbia, Canada
Decoding Fibroblast Heterogeneity and Functions in Tissue Fibrosis and Regeneration

Shannon J. Turley, Genentech, Inc., USA
Understanding Fibroblast Heterogeneity in Fibrosis and Cancer via scRNA-seq

Robert E. Schwartz, Weill Cornell Medicine, USA
Spatial Transcriptomics in Lethal COVID-19: Fibroblasts and Pulmonary Fibrosis

Scott M. MacDonnell, Regeneron Pharmaceuticals, Inc., USA
Keloids: Translational Model for Assessing Anti-Fibrotics in Humans

Fibrosis Resolution: Repair and Regeneration (X3)

David Lagares, Massachusetts General Hospital/Harvard Medical School, USA
Cell-Specific Senolytics to Reverse Established Lung Fibrosis

Emerging Biology and Function of Genetic Links to NAFLD/NASH (X4)

Paola Dongiovanni, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Italy
Compound Genetic Mutations and NASH

Yaron Rotman, NIDDK, National Institutes of Health, USA
Insights into HSD17beta13 Biology

Daniel Lindén, AstraZeneca, Sweden
Advances in PNPLA3 Function in NASH

Fibrosis Biomarkers: from Identification to Clinical Application (X3)
Naftali Kaminski, Yale University School of Medicine, USA
Understanding Cell-Cell Communication in Lung Fibrosis Through scRNA-seq Data

Carine Boustany, Boehringer Ingelheim, USA
Biomarkers of Lung Fibrosis: Learnings from Clinical Studies

Morten A. Karsdal, Nordic Bioscience A/S, Denmark
The Role of Formation and Degradation of the Interstitial and Basement Membrane ECM in the Pathogenesis of Fibrotic Liver Diseases

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
(X4)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
(X3)

FRIDAY, MARCH 24

Departure